Gabapentin Withdrawal & Tapering Guide
gabapentin
Boxed Warning
Respiratory depression risk when used with CNS depressants, particularly opioids. Increased risk of suicidal thoughts and behavior (anticonvulsant class warning).
In short
Gabapentin (gabapentin) is a Gabapentinoid with a half-life of 5–7 hours. Short half-life with non-linear absorption. It is also sold as Neurontin, Gralise, Horizant.
- Class
- Gabapentinoid
- Half-life
- 5–7 hours
- Common doses
- 100mg, 300mg, 600mg, 800mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Gabapentin is an anticonvulsant approved for epilepsy (adjunctive therapy for partial seizures) and postherpetic neuralgia. It is widely prescribed off-label for neuropathic pain, anxiety, insomnia, and alcohol/benzodiazepine withdrawal. Despite its name, it does not bind GABA receptors.
100mg, 300mg, 600mg, 800mg
Capsules: 100mg, 300mg, 400mg; Tablets: 600mg, 800mg; Oral solution: 250mg/5mL; Extended-release tablets (Gralise): 300mg, 600mg
Category C (risk cannot be ruled out)
Mechanism of Action
Binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and subsequent release of excitatory neurotransmitters (glutamate, norepinephrine, substance P). Does not bind GABA receptors or affect GABA uptake/metabolism.
Taper Notes
Short half-life with non-linear absorption. Multiple daily doses needed. Water titration method works well for precise reductions.
Hyperbolic Tapering Guidance
Reduce by no more than 10% per step. Non-linear pharmacokinetics mean absorption decreases at higher doses. Capsules can be opened for water titration.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Opioids — increased risk of respiratory depression and sedation
- CNS depressants — additive sedation
- Antacids containing aluminum/magnesium reduce gabapentin absorption by ~20% — dose gabapentin ≥2 hours after antacids
Food Interactions
- Food modestly increases absorption (~14%)
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to gabapentin
Toxicity
Relatively low acute toxicity. Respiratory depression when combined with opioids or CNS depressants. Suicidal ideation (class warning for anticonvulsants). Physical dependence with chronic high-dose use.
Pharmacokinetics
ADME Profile
Absorbed via L-amino acid transport system in the small intestine. Bioavailability is dose-dependent (inversely proportional): ~60% at 300mg, ~35% at 1600mg. Tmax 2–3 hours. Food modestly increases absorption.
~0.8 L/kg (58 L in 72 kg individual)
Not appreciably metabolized in humans. No CYP involvement. Excreted unchanged.
Renal (~100% excreted unchanged). Clearance is proportional to creatinine clearance.
<3% (not significantly protein bound)
~120–130 mL/min (renal clearance, similar to GFR)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Gabapentinoid medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 300 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (300 mg start) |
|---|---|---|
| Start | 100% | 300 mg |
| Step 1 | 90% | 270 mg |
| Step 2 | 81% | 243 mg |
| Step 3 | 73% | 218.7 mg |
| Step 4 | 66% | 196.8 mg |
| Step 5 | 59% | 177.1 mg |
| Step 6 | 53% | 159.4 mg |
| Step 7 | 48% | 143.5 mg |
| Step 8 | 43% | 129.1 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Gabapentin, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Gabapentin
What are the withdrawal symptoms of Gabapentin (gabapentin)?
Common withdrawal symptoms of Gabapentin (gabapentin) include: anxiety, insomnia, nausea, sweating, seizure risk at high doses, pain rebound. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Gabapentin (gabapentin)?
Short half-life with non-linear absorption. Multiple daily doses needed. Water titration method works well for precise reductions. Reduce by no more than 10% per step. Non-linear pharmacokinetics mean absorption decreases at higher doses. Capsules can be opened for water titration.
Can I stop Gabapentin cold turkey?
Stopping Gabapentin abruptly is not recommended. Its half-life is 5–7 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Gabapentin stay in your system?
Gabapentin (gabapentin) has a half-life of 5–7 hours. A drug is mostly cleared after about five half-lives, so Gabapentin is largely out of the body roughly 25 to 35 hours after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Recent discussions about Gabapentin
What members tapering Gabapentin are asking and reporting right now. Personal experience, not medical advice.
Sources & References
Gabapentin (gabapentin) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms
- Royal College of Psychiatrists — Pregabalin and gabapentin — UK clinical guidance on pregabalin and gabapentin prescribing
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.